COVID-19 : les thérapeutiques

There are different therapeutics options to treat COVID-19 at different stages of the disease. While large-scale prophylaxis in the general population now relies on vaccination, antiviral molecules such as monoclonal antibodies are being evaluated for post-exposure prophylaxis, particularly in patients at high risk of severe forms of COVID-19. The early phase of the disease, whether symptomatic or not, could benefit from stimulation of natural antiviral immunity such as type 1 interferons and/or from the administration of antiviral treatments including monoclonal antibodies. In more advanced stages of the disease, corticosteroid therapy has shown a benefit on mortality in hospitalized patients requiring oxygen support. Despite numerous disappointments of antiviral treatments, antiviral molecules are still being evaluated as well as targeted anti-inflammatory therapies.